Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study

Peter Bytzer; Stephen Pratt; Eric Elkin; Jørgen Næsdal; Elisabeth Sörstadius

doi:10.1007/s40256-012-0001-4

Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study

Peter Bytzer, Stephen Pratt, Eric Elkin, Jørgen Næsdal, Elisabeth Sörstadius

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

9 Citationer (Scopus)

Abstract

Continuous low-dose acetylsalicylic acid (aspirin; ASA) is a mainstay of cardiovascular (CV) risk management. It is well established, however, that troublesome upper gastrointestinal (GI) symptoms are commonly experienced among low-dose ASA users.

Originalsprog	Engelsk
Tidsskrift	American Journal of Cardiovascular Drugs
Vol/bind	13
Udgave nummer	1
Sider (fra-til)	27-35
Antal sider	9
ISSN	1175-3277
DOI	https://doi.org/10.1007/s40256-012-0001-4
Status	Udgivet - feb. 2013

Adgang til dokumentet

10.1007/s40256-012-0001-4

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study. / Bytzer, Peter; Pratt, Stephen; Elkin, Eric et al.
I: American Journal of Cardiovascular Drugs, Bind 13, Nr. 1, 02.2013, s. 27-35.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{f4575825a667471ba073897db75265d7,

title = "Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study",

abstract = "Continuous low-dose acetylsalicylic acid (aspirin; ASA) is a mainstay of cardiovascular (CV) risk management. It is well established, however, that troublesome upper gastrointestinal (GI) symptoms are commonly experienced among low-dose ASA users.",

author = "Peter Bytzer and Stephen Pratt and Eric Elkin and J{\o}rgen N{\ae}sdal and Elisabeth S{\"o}rstadius",

year = "2013",

month = feb,

doi = "10.1007/s40256-012-0001-4",

language = "English",

volume = "13",

pages = "27--35",

journal = "American Journal of Cardiovascular Drugs",

issn = "1175-3277",

publisher = "Adis International Ltd",

number = "1",

}

TY - JOUR

T1 - Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management

T2 - a prospective observational study

AU - Bytzer, Peter

AU - Pratt, Stephen

AU - Elkin, Eric

AU - Næsdal, Jørgen

AU - Sörstadius, Elisabeth

PY - 2013/2

Y1 - 2013/2

N2 - Continuous low-dose acetylsalicylic acid (aspirin; ASA) is a mainstay of cardiovascular (CV) risk management. It is well established, however, that troublesome upper gastrointestinal (GI) symptoms are commonly experienced among low-dose ASA users.

AB - Continuous low-dose acetylsalicylic acid (aspirin; ASA) is a mainstay of cardiovascular (CV) risk management. It is well established, however, that troublesome upper gastrointestinal (GI) symptoms are commonly experienced among low-dose ASA users.

U2 - 10.1007/s40256-012-0001-4

DO - 10.1007/s40256-012-0001-4

M3 - Journal article

C2 - 23315343

SN - 1175-3277

VL - 13

SP - 27

EP - 35

JO - American Journal of Cardiovascular Drugs

JF - American Journal of Cardiovascular Drugs

IS - 1

ER -